Completed PHASE2 INTERVENTIONAL 4-arm NCT01675882

Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy (VIPES)

A Double-blind, Placebo-controlled, Randomized Trial to Study the Viaskin Peanut's Efficacy and Safety for Treating Peanut Allergy in Children and Adults.

Sponsor: DBV Technologies

Conditions Peanut Allergy

Interventions Viaskin Peanut 100 mcg Viaskin Peanut 250 mcg Viaskin Peanut 50 mcg Viaskin Placebo

Updated 8 times since 2017 Last updated: Sep 28, 2021 Started: Aug 31, 2012 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Peanut Allergy, this trial is completed. The trial is conducted by DBV Technologies and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Nov 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Nov 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

DBV Technologies

Data source: DBV Technologies

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bordeaux, France , Boston, United States , Bydgoszcz, Poland , Chicago, United States , Cincinnati, United States , Dallas, United States , Lille, France , Lodz, Poland , Mississauga, Canada , Nice, France and 13 more locations